India’s First Β· Multi-Cancer Early Detect Platform

The end of untreatable.

ORAONCO challenges the dogma that cancer is a genetic disease cause by random genetic mutations and detects multiple cancers at pre-clinical stage using oral microbiome and mitochondrial fuctions.

Healthy Cell Membrane Intact ATP β€” Normal vs PRE-CLINICAL Cancer Cell Ion Channel Leak Mitochondrial Defect LPS / Toxins PRE-CLINICAL DETECTION Β· STAGE 0–1 ORAONCO Β· MULTI-CANCER MOLECULAR DETECTION
10M+
Molecules per sample
95%
Sensitivity
82%
Specificity
10B+
Metadata points

The platform currently measures defects in mitochondria and oral microbiome- mitochondria crosstalk β€” using frontier technologies to detect oral cancer (OSCC).

01
Early Detection

Deciphering hidden cancer cues in mitochondrial frequency.

Genefitletics’ cancer detect platform combines throughput sequencing, computational technologies & machine learning to detect oral cancer at pre-clinical stage β€” earleir than is currently possible with MRI, invasive biopsies, routine blood diagnostics, or mutation-based approaches.

πŸ”¬
Throughput Sequencing
Clinically validated sequencing technology that deciphers downstream functions of oral microbiome, mitochondria & human cells β€” quantifying 10 million molecules per biological sample into 27 molecular pathways.
🧬
System Biology
Confluence of biophysics and exponential technologies creates a biological atlas that identifies pre-clinical signatures of oral cancer, leveraging 10 billion cellular and phenotype metadata sets.
πŸ€–
Machine Learning Platform
Every month, new biological samples give a digital view of human biology at a cellular levl that further trains our ML algorithms for better efficacy and results.

Genefitletics Diagnostics

India’s first early detection molecular diagnostic test.

ORAONCO β€” Test Overview

10 million molecules from biological samples deciphered to detect oral cancer at pre- PET scan, pre- profilferation stage.

India’s first & only early detection molecular diagnostic test that measures & quantifies pre-clinical molecular biomarkers associated with oral cancer.

This non-invasive test collects & analyses 10 million molecules from your biological sample β€” identifying dysregulated microbial pathways & defects in mitochondria to detect oral cancer at stage 0–1.

95%
Sensitivity
82%
Specificity
0.764
AUC
10B+
Validation data points
Annual Subscription
β‚Ή25,000
What we analyse
Measures & quantifies inflammatory & carcinogenic molecular pathways associated with early onset of oral cancers β€” earlier than possible with invasive biopsies & mutation-based approaches.
Why current tests miss pre-clinical cancer
MRI, PET scans & biopsies detect cancer after it has physically manifested and tumour shows up. DNA mutation-based tests only flag genetic markers β€” not the molecular dysfunction that precedes breakdown in energetic processes of mitochondria.
Precision cancer-modifiable biotherapeutics
Precision biotherapeutics that eliminate carcinogenic & inflammatory molecules at pre-PET scan stage β€” integrated with diagnostic & treatment protocols of healthcare practitioners & oncologists.
Preventing recurrence model
Combines precision biotherapeutics & alternative therapies (red light, HBOT & more) with standard of care β€” addressing the molecular root cause to prevent cancer from recurring after treatment.
Currently operational
Oral Cancer (OSCC) β€” with 95% sensitivity & 82% specificity. Early detection studies for brain cancer is ongoing.
CAP certified laboratory
Your sample is analysed in an Indian CAP-certified laboratory meeting internationally recognised accuracy standards β€” testament to precise, reliable results.

02
Platform Science

Biophysics , Mitochondiral Energetics biochemistry & machine learning as the centrepiece of cancer biology.

Our cellular energetics platform translates cellular data into early cancer detection signals & delivers precise restorative interventions tied to clinical practice that drives big anatomical results.

πŸ”¬
Detects oral cancers at pre-clinical stage β€” earlier than MRI, invasive biopsies, routine blood diagnostics & mutation-based approaches
🧬
10 billion+ metadata sets of sequenced samples & disease phenotype data as the starting point for energetic investigation into cancer diagnostics and mitochondrial reprogramming for large scale morphogenetic goals
πŸ€–
Continuously validated ML models applied to individual biological data to elucidate early signals of pathogenesis & onset of multiple cancer forms
⚑
Identifies dysregulated microbial pathways & defects in mitochondria β€” the earliest detectable pre-cancer signals
πŸ“Š
Disease & non-disease cohort analysis β€” systematically identifies defects in mitochondria and companion molecular signatures that differentiate between cancer onset and healthy state
βœ“
Validated on independent unseen cohorts β€” not just training data. Every molecular signature and mitochondrial dysregulation signals used for detection is independently validated before clinical use
mtDNA Energetics MITOCHONDRIAL ENERGETICS βš›οΈ BIOPHYSICS Bioelectric field membrane potential 🧬 BIOCHEMISTRY Microbiome pathways dysregulation signals πŸ€– MACHINE LEARNING Pattern recognition molecular signatures ORAL MICROBIOME 10M+ molecules per sample SALIVA ANALYSIS Pre-clinical stage 0–1 detection SENSITIVITY 95% SPECIFICITY 82% AUC SCORE 0.764 CANCER BIOLOGY Β· CENTREPIECE PLATFORM

Cancer Modifiable Therapeutics

A complete non-toxic biotherapeutics stack with biology-based dosages.

The therapeutics recommendation engine mathematically combines insights from 40,000+ clinical study references, dysregulated pathways and nutrition ontology consisting of 100,000 dietary and molecular substrates to deliver non-pharmacological, non-toxic regenerative therapeutic interventions that eliminate carcinogenic & inflammatory molecules before cancer proliferates.

πŸ₯—
317
Foods
Superfood, enjoy, moderate & avoid + insulin response prediction
πŸ’Š
28
Supplements
Vitamins & minerals with biology-based dosages
🫐
24
Antioxidants
With biology-based dosages to suppress carcinogenic molecules
πŸ§ͺ
18
Amino Acids
With biology-based dosages
🌿
54
Food Extracts
With biology-based dosages
🦠
39
Biotics
Prebiotics, probiotics & synbiotics
βš—οΈ
6
Postbiotics
Microbial metabolic byproducts
🦷
6
Oral Microbiome Support
Targeted oral biology molecules
πŸ”‹
14
Mitochondria Support
To correct mitochondrial dysfunction
🧬
9
Peptides & Bioregulators
Bioactive molecules with biology-based dosages
πŸ”¬
2
Exopolysaccharides
With biology-based dosages
πŸ₯
+Alt
Alternative Therapies
Red light, HBOT & more combined for recurrence prevention

03
Preventative Oncology

Precision biotherapeutics combined with standard of care.

Therapeutic interventions are combined with standard of care for patients who are in advanced stage of oral cancer and /or targeting preventive recurrence. This brings a perfect confluence of modern medicine with mitochondrial energetics to give additional insights for oncologists and healthcare practitioners- delivering disease modifiable and health promoting outcomes.

πŸ§‘β€βš•οΈ
Confluence of Data & Human Touch
Your results & interventions are followed by a detailed deep dive into your cellular analysis, microbiome behaviour, cancer biomarkers & associated biotherapeutics by our clinical team. The test complements the standard-of-care and drives efficacy first approach in partnership with oncologists & healthcare practitioners.
πŸ’Š
Drug–Biomarker Interaction
Your oncologist can access the molecular interaction between standard of care therapies & microbial signatures to evaluate drug efficacy and adjust protocols in real time.
πŸ₯
Closing the Care Gap
A separate platform for your healthcare practitioners β€” molecular-level insights, cancer biomarkers & precision biotherapeutics integrated seamlessly with standard care practices.
🚩
Red Flag Real-Time Tracking
Track how daily choices impact growth or suppression of carcinogenic & inflammatory molecules. Red flag alerts when permissible biology-based dosages are exceeded.
πŸ”„
Molecular Feedback Loop
Quarterly tracking of intervention efficacy and its impact on your current cancer phenotype β€” driving quarterly revision of biotherapeutics to match your evolving molecular state.
πŸ”
Recurrence Prevention Model
Precision biotherapeutics + alternative therapies (red light, HBOT) + standard of care therapies combined as a comprehensive post-treatment recurrence prevention protocol.

Test Details

A complete bology manual before your subscribe

🧫
Sample Collection
Non-invasive saliva sample collected at home. No biopsy, no blood draw, no clinic visit required.
πŸ”¬
Molecular Signals Measured
Molecular pathways underlying oral & gut microbial dysbiosis & defects in mitochondria associated with multiple cancers at pre-clinical stage.
🎯
Who This Test Is For
Tobacco & alcohol users Compromised oral health Hypertension / hyperglycaemia Obesity / Type 2 diabetes Sexual dysfunction Age 25–60 years
πŸ”„
Re-testing Frequency
Re-test every 6 months. A “Not Detected” result does not rule out cancer. Early molecular signals require longitudinal monitoring. A “Detect” signal is corroborated with standard-of-care diagnosis tools
πŸ”’
Data Privacy
Molecular & longitudinal data is safeguarded with multiple encryption layers. Genefitletics never shares or sells your data to employers, insurers, or third parties.
Detection Accuracy
Validated on 10 billion molecular metadata points across disease & non-disease cohorts.
Sensitivity95%
Specificity82%
Sensitivity 95% & specificity 82% validated for Oral Cancer (OSCC). Studies for brain cancer is ongoing.
πŸ…
CAP Certified Laboratory
Analysed in an Indian CAP-certified lab β€” meeting the globally recognised College of American Pathologists accuracy standard.
Cancer Pipeline
Oral Cancer (OSCC)
Brain Cancer

Genefitletics Approach

Clinical approach behind our cancer diagnostics models.

A rigorous 3-step scientific methodology from clinical cohort curation through to independent validation.

1
Cohort Design & Curation
Carefully design & curate disease and non-disease cohorts from existing clinical metadata β€” ensuring clean, representative biological samples for each cancer type.
2
Molecular Signature Identification
Systematically & statistically analyse both cohorts to identify & combine molecular signatures β€” consisting of both microbiome & mitochondrial signals β€” that differentiate disease from non-disease state.
3
Independent Validation
Validate molecular signatures on an unseen, independent cohort β€” ensuring detection accuracy is real-world grade, not just training-data performance.

Cancer Discovery Research

Ongoing multi-cancer discovery studies.

Apart from Oral Cancer, Genefitletics is conducting ongoing clinical studies to develop test for early detection of brain cancer.

🦷
Oral & Throat Cancer (OSCC)
Our first commercially available test. 95% sensitivity, 82% specificity β€” validated on internal clinical studies. Non-invasive saliva-based collection.
● Live
🧠
Brain Cancer
Identifying microbiome & mitochondrial signatures associated with early onset of brain cancer. Validation study in works.
● Validation Study
πŸ“„
Publication
Salivary microbiome signature for early detection of oral & throat cancer.
Internal clinical validation study. Access subject to research agreement.
Request Access via WhatsApp β†’

Important Information

Understanding your test results.

πŸ”’
Data Privacy
Your molecular & longitudinal data is protected with multiple layers of encryption. We do not provide your information or results to employers or health insurers. Genefitletics never sells your data to third parties.
πŸ…
CAP Certified
Your sample is analysed in an Indian CAP-certified laboratory to meet CAP standards β€” a global testimony of accurate results and rigorous quality control in molecular diagnostics.
πŸ”„
Re-testing Protocol
To evaluate your risk accurately, re-test every 6 months. A result of “Not Detected” does not rule out cancer β€” early molecular signals require longitudinal monitoring to track trajectory.
πŸ‘¨β€βš•οΈ
Complementary to Standard Care
ORAONCO should be used in conjunction with routine tests such as biopsy, PET scans & other investigations as recommended by your healthcare provider. A “Detected” result requires confirmation via histopathological methods.

Intended Use: The test is intended to be used as a tool to evaluate the biological signals associated with OSCC. ORAONCO is recommended for adults with medium to high risk for oral cancer, Type 2 diabetes, obesity, or hypertension β€” and those with a history of smoking, chewing tobacco, vaping, alcohol consumption, or high risk of HPV. Results should be interpreted in relation to medical history and current symptoms.


Get Started

Detect cancer before it becomes untreatable.

India’s first & only multi-cancer early detection molecular diagnostic test β€” non-invasive, saliva-based, and validated on 10 billion molecular data points.

βœ“
10M+ molecules quantified per sample
βœ“
Detects oral cancer at stage 0–1 (95% sensitivity, 82% specificity)
βœ“
Non-invasive saliva sample β€” at home
βœ“
Cancer-modifiable non-toxic biotherapeutics stack
βœ“
CAP certified laboratory analysis
βœ“
Practitioner platform + molecular feedback loop
ORAONCO
Multi-Cancer Early Detection
Annual Subscription β€” Oral Cancer (OSCC) + ongoing pipeline
β‚Ή25,000
per year Β· includes full access to platform, biotherapeutics & review
Questions? Email Support@genefitletics.com or chat on WhatsApp
Genefitletics

FREE
VIEW